The exercise period for subscription warrants in Series TO 4 (the "Subscription Warrants") that were issued in conjunction with
In total,
In order for the subscription warrants not to expire and lose value, they must be actively sold by
"At the same time, progress in developing the IDO 8 project for a clinical phase confirms our concept that tolerogenic dendritic cells can be used as a platform technology to treat many other difficult conditions and illnesses. Lessons from the IDO 8 project can be translated directly to the company's subsequent IDO T project. IDO T has the potential to become a treatment for inducing tolerance against undesirable upregulation of the immune system in connection with organ transplants. We are now accelerating our development in this indication and preparing to start preclinical studies." says
In the event all Subscription Warrants are exercised for subscription of shares, the Company will raise approximately MSEK 18 before issue costs. The net liquidity of approximately MSEK 17 is intended for use for the following purposes, indicated in order of priority:
- Phase I/IIa clinical trial in IDO 8, approximately MSEK 5
- Preclinical studies for IDO T, approximately MSEK 5
- Business development and academic partnerships, approximately MSEK 3
- Other operating capital reinforcement for financing operating activities, approximately MSEK 4
Terms for the Subscription Warrants:
- The subscription price has been set to
SEK 2.06 per share. -
The subscription price has been defined as seventy (70) percent of a volume-weighted average of the price of the Company's share during the period
6-17 September 2021 . The volume-weighted average of the price forIdogen during the period amounted toSEK 2.94 . -
The exercise period runs from
September 21 to October 5, 2021 . - The issue volume is 9,121,654 Subscription Warrants. If the Subscription Warrants are fully exercised, the Company will raise approximately MSEK 18 before issue costs.
-
An announcement of the outcome is planned to
October 8, 2021 . -
Conversion of interim shares into shares is planned to
October 20, 2021 .
Note that Subscription Warrants that have not been sold by
Exercise of subscription warrants
Nominee shareholder Subscription Warrants
If the warrant holder has Subscription Warrants in a deposit account, in an investment savings account or endowment policy (nominee shareholder ownership), subscription and payment will take place with the administrator. The warrant holder should contact their administrator well in advance for further instructions regarding exercising of the Subscription Warrants.
Directly registered Subscription Warrants (securities account)
Registration via a registration form available on the websites of
For questions concerning the Series TO 4 subscription warrants, please contact:
Phone: +46 (0)8-463 80 00
Email: emission@penser.se
For further information, please contact:
Phone: +46 (0) 709 18 00 10
Email: anders.karlsson@idogen.com
The information was submitted for publication, through the agency of the contact person set out above, for publication on September 21, 2021 at
Certified Adviser
The company's Certified Adviser is
IMPORTANT INFORMATION
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in
https://news.cision.com/idogen/r/exercise-period-for-series-to-4-subscription-warrants-in-idogen-begins-today,c3418473
https://mb.cision.com/Main/12368/3418473/1470745.pdf
(c) 2021 Cision. All rights reserved., source